Bivalent mRNA-1273.214 vaccine effectiveness against SARS-CoV-2 omicron XBB* infections.

Hiam ChemaitellyHoussein H AyoubSawsan AlMukdadJeremy Samuel FaustPatrick TangPeter CoyleHadi M YassineAsmaa A Al ThaniHebah A Al-KhatibMohammad R HasanZaina Al-KanaaniEinas Al-KuwariAndrew JeremijenkoAnvar H KaleeckalAli N LatifRiyazuddin M ShaikHanan F Abdul-RahimGheyath K NasrallahMohamed G Al-KuwariAdeel Ajwad ButtHamad E Al-RomaihiMohamed H Al-ThaniAbdullatif Al-KhalRoberto BertolliniLaith Jamal Abu-Raddad

Published in: Journal of travel medicine (2023)

Effectiveness of the 50-μg mRNA-1273.214 bivalent vaccine against SARS-CoV-2 infection was modest at 25% in a matched, retrospective, cohort study in Qatar comparing infection incidence in the bivalent cohort to that in the national no-recent-vaccination resident cohort. XBB* immune evasion, immune imprinting effects, or both, may explain findings.

Keyphrases

sars cov
randomized controlled trial
respiratory syndrome coronavirus
systematic review
quality improvement
binding protein
risk factors
patient safety